ERAS
Price
$9.55
Change
+$1.25 (+15.04%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
2.36B
63 days until earnings call
Intraday BUY SELL Signals
LQDA
Price
$38.86
Change
-$1.13 (-2.83%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
3.48B
56 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs LQDA

Header iconERAS vs LQDA Comparison
Open Charts ERAS vs LQDABanner chart's image
Erasca
Price$9.55
Change+$1.25 (+15.04%)
Volume$128.98K
Capitalization2.36B
Liquidia
Price$38.86
Change-$1.13 (-2.83%)
Volume$31.87K
Capitalization3.48B
ERAS vs LQDA Comparison Chart in %
ERAS
Daily Signal:
Gain/Loss:
LQDA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ERAS vs. LQDA commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and LQDA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (ERAS: $8.31 vs. LQDA: $39.99)
Brand notoriety: ERAS and LQDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 269% vs. LQDA: 138%
Market capitalization -- ERAS: $2.36B vs. LQDA: $3.48B
ERAS [@Biotechnology] is valued at $2.36B. LQDA’s [@Biotechnology] market capitalization is $3.48B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 0 FA rating(s) are green whileLQDA’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 0 green, 5 red.
  • LQDA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ERAS and LQDA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 4 TA indicator(s) are bullish while LQDA’s TA Score has 4 bullish TA indicator(s).

  • ERAS’s TA Score: 4 bullish, 4 bearish.
  • LQDA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ERAS and LQDA are a good buy in the short-term.

Price Growth

ERAS (@Biotechnology) experienced а +60.74% price change this week, while LQDA (@Biotechnology) price change was +29.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.44%. For the same industry, the average monthly price growth was +2.31%, and the average quarterly price growth was +42.34%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 19, 2026.

LQDA is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (-0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LQDA($3.48B) has a higher market cap than ERAS($2.36B). ERAS YTD gains are higher at: 123.387 vs. LQDA (15.947). LQDA has higher annual earnings (EBITDA): -102.75M vs. ERAS (-131.32M). ERAS has more cash in the bank: 288M vs. LQDA (157M). ERAS has less debt than LQDA: ERAS (48.3M) vs LQDA (199M). LQDA has higher revenues than ERAS: LQDA (69.2M) vs ERAS (0).
ERASLQDAERAS / LQDA
Capitalization2.36B3.48B68%
EBITDA-131.32M-102.75M128%
Gain YTD123.38715.947774%
P/E RatioN/AN/A-
Revenue069.2M-
Total Cash288M157M183%
Total Debt48.3M199M24%
FUNDAMENTALS RATINGS
LQDA: Fundamental Ratings
LQDA
OUTLOOK RATING
1..100
30
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
PROFIT vs RISK RATING
1..100
4
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASLQDA
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 11 days ago
87%
Bearish Trend 29 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
LQDA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CFLGX25.430.06
+0.24%
ClearBridge Tactical Dividend Income A
HHCZX18.03-0.06
-0.33%
NexPoint Event Driven Z
JDBAX48.36-0.25
-0.51%
Janus Henderson Balanced A
AFDIX48.08-0.33
-0.68%
American Century Large Cap Equity Inv
MIFOX28.56-0.47
-1.62%
Marsico Focus Institutional

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+10.73%
RVMD - ERAS
61%
Loosely correlated
+1.06%
NUVL - ERAS
48%
Loosely correlated
+6.59%
ZNTL - ERAS
47%
Loosely correlated
+0.86%
CRNX - ERAS
47%
Loosely correlated
+2.04%
XNCR - ERAS
45%
Loosely correlated
+3.66%
More

LQDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with CGON. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LQDA
1D Price
Change %
LQDA100%
+4.99%
CGON - LQDA
34%
Loosely correlated
+5.57%
DMAC - LQDA
34%
Loosely correlated
+4.24%
GOSS - LQDA
33%
Loosely correlated
-4.14%
UNCY - LQDA
32%
Poorly correlated
+9.62%
ERAS - LQDA
32%
Poorly correlated
+10.73%
More